Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219209 | 0.86 | ALDH1A1 (0.80) | ALDH1A1CYP3A4GPR35MAPTTDP1 | |
| SCHEMBL10885332 | 0.86 | ALDH1A1 (0.57) | ALDH1A1CYP3A4GPR35MEN1KMT2A | |
| SCHEMBL8449685 | 0.82 | ALDH1A1 (0.66) | ALDH1A1CYP3A4GPR35MEN1KMT2A | |
| Nitrogen SCHEMBL28796026 | 0.82 | ALDH1A1 (0.74) | ALDH1A1CYP3A4GPR35MAPTTDP1 | |
| SCHEMBL5123353 | 0.80 | GAA (0.60) | ALDH1A1CYP3A4GPR35MEN1KMT2A | |
| SCHEMBL17132338 | 0.80 | ALDH1A1 (0.62) | ALDH1A1CYP3A4GPR35MEN1KMT2A | |
| SCHEMBL29448460 | 0.80 | ALDH1A1 (1.00) | ALDH1A1CYP3A4GPR35MEN1KMT2A | |
| SCHEMBL11349866 | 0.80 | ALDH1A1 (0.71) | ALDH1A1CYP3A4GPR35ALOX15TDP1 | |
| SCHEMBL909587 | 0.80 | ALDH1A1 (1.00) | ALDH1A1CYP3A4GPR35MEN1KMT2A | |
| Bromide SCHEMBL29483842 | 0.78 | ALDH1A1 (0.96) | ALDH1A1CYP3A4GPR35MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064565-A1 | TRICYCLIC BENZOTHIAZOLES FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| EP-3575303-B1 | IMIDAZOPYRIDAZINE COMPOUND | HANMI PHARMACEUTICAL CO LTD (KR) | 2022-07-06 | — | — | EP | disclosed |
| EP-3575303-B1 | IMIDAZOPYRIDAZINE COMPOUND | HANMI PHARMACEUTICAL CO LTD (KR) | 2022-07-06 | — | — | EP | disclosed |
| CN-110234653-B | Imidazopyridazine compounds | 韩美药品株式会社 | 2022-02-08 | — | — | CN | disclosed |
| EP-3514153-B1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HANMI PHARM IND CO LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3514153-B1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HANMI PHARM IND CO LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3789386-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2021-03-10 | — | — | EP | disclosed |
| EP-3789386-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2021-03-10 | — | — | EP | disclosed |
| US-10781217-B2 | Imidazopyridazine compound | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2020-09-22 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| CN-101472585-A | Antibacterial compositions | PROLYSIS LTD (GB) | 2009-07-01 | — | — | CN | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2006125208-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | WAYNE STATE UNIVERSITY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | ALDH1A1 3469/4885CYP3A4 849/4885GPR35 2303/4885 |
| US-10781217-B2 | Imidazopyridazine compound | MKI67, ING2, API5 | ALDH1A1 31/4885CYP3A4 127/4885GPR35 2095/4885 |
| US-20090005420-A1 | Inhibitors of Matrix Metallaproteinases | MMP9, MMP1, MMP2 | ALDH1A1 333/4885CYP3A4 2685/4885GPR35 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.